Cullinan Oncology Revenue and Competitors

Boston, MA USA

Location

$379.7M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Cullinan Oncology's estimated annual revenue is currently $18.9M per year.(i)
  • Cullinan Oncology's estimated revenue per employee is $178,679
  • Cullinan Oncology's total funding is $379.7M.
  • Cullinan Oncology's current valuation is $598M. (January 2022)

Employee Data

  • Cullinan Oncology has 106 Employees.(i)
  • Cullinan Oncology grew their employee count by 25% last year.

Cullinan Oncology's People

NameTitleEmail/Phone
1
SVP, CommunicationsReveal Email/Phone
2
VP, Clinical Development Operations & Clinical Program ManagementReveal Email/Phone
3
VP Investor RelationsReveal Email/Phone
4
VP, Preclinical ResearchReveal Email/Phone
5
VP and Head Information TechnologyReveal Email/Phone
6
VP, Preclinical R&DReveal Email/Phone
7
VP, ControllerReveal Email/Phone
8
SVP, Head Clinical DevelopmentReveal Email/Phone
9
VP, Head RegulatoryReveal Email/Phone
10
VP Clinical PharmacologyReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Cullinan Oncology?

Cullinan Oncology is focused on investing in and developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. Sourced from the Cullinan dry lab as well as external collaborators, Cullinan’s assets are managed by a single, highly experienced team of oncology professionals and drug developers across a lean, capital efficient operating model.

keywords:N/A

$379.7M

Total Funding

106

Number of Employees

$18.9M

Revenue (est)

25%

Employee Growth %

$598M

Valuation

N/A

Accelerator

Cullinan Oncology News

2022-03-30 - Cullinan Oncology to Participate in Upcoming Virtual ...

CAMBRIDGE, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) a biopharmaceutical company focused...

2022-03-30 - Cullinan Oncology Reports Inducement Grants Under Nasdaq ...

Cullinan Oncology is a biopharmaceutical company that is developing a diversified pipeline of targeted therapeutic candidates across multiple...

2022-03-22 - Cullinan Oncology Announces Clinical and Regulatory ...

Cullinan Oncology is a biopharmaceutical company that is developing a diversified pipeline of targeted therapeutic candidates across multiple...

2020-12-17 - Cullinan Oncology, Inc. announced that it has received $131.200119 million in funding from a group of investors

Cullinan Oncology, LLC announced that it has issued 66,599,045 series C preferred stock at a price of $1.97 per share for gross proceeds of $131,200,119.65 on December 17, 2020. The series C round of funding was led by Foresite Capital Management, LLC. The transaction included participation from ...

2020-12-17 - Cullinan Oncology Closes $131.2 Million Series C Financing

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cullinan Oncology, LLC, a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients, announced today the closing of an oversubscribed $131.2 millio ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$15.4M106N/AN/A
#2
$10.8M106-12%N/A
#3
$4.5M107-29%$173.3M
#4
$22.5M10727%N/A
#5
$15.5M107N/AN/A